TY - JOUR
T1 - Neoadjuvant nab-paclitaxel and gemcitabine in borderline resectable or locally advanced unresectable pancreatic adenocarcinoma in patients who are ineligible for FOLFIRINOX
AU - Peterson, Shawn L.
AU - Husnain, Muhammad
AU - Pollack, Terri
AU - Pimentel, Agustin
AU - Loaiza-Bonilla, Arturo
AU - Westendorf-Overley, Colleen
AU - Ratermann, Kelley
AU - Anthony, Lowell
AU - Desimone, Philip
AU - Goel, Gaurav
AU - Kudrimoti, Mahesh
AU - Dineen, Sean
AU - Tzeng, Ching Wei D.
AU - Hosein, Peter J.
N1 - Publisher Copyright:
© 2018 International Institute of Anticancer Research. All rights reserved.
PY - 2018/7
Y1 - 2018/7
N2 - Background/Aim: Combination nab-paclitaxel/ gemcitabine (AG) is superior to gemcitabine in patients with metastatic pancreatic cancer (PC). There are limited data for AG in borderline resectable (BR) or locally advanced pancreatic cancer (LAPC). Herein, we report our experience with neoadjuvant AG for BR/LAPC in patients ineligible for FOLFIRINOX. Patients and Methods: This retrospective series, included patients with BR/LAPC who received AG as neoadjuvant therapy for 3-4 months followed by radiation, then re-evaluation for surgery. Results: Between 10/2013-2/2018, 32 patients (22 BR, 10 LAPC) were treated with this approach. Median age was 70 years. Nine patients were converted to resectability by imaging; six had R0 resections (19%), five (16%) achieved a partial response and 24 (75%) had stable disease. Conclusion: In this small series, the R0 resection rate and response rate were 19% and 16% respectively. These data suggest that neoadjuvant AG may be an alternate option for patients ineligible for FOLFIRINOX.
AB - Background/Aim: Combination nab-paclitaxel/ gemcitabine (AG) is superior to gemcitabine in patients with metastatic pancreatic cancer (PC). There are limited data for AG in borderline resectable (BR) or locally advanced pancreatic cancer (LAPC). Herein, we report our experience with neoadjuvant AG for BR/LAPC in patients ineligible for FOLFIRINOX. Patients and Methods: This retrospective series, included patients with BR/LAPC who received AG as neoadjuvant therapy for 3-4 months followed by radiation, then re-evaluation for surgery. Results: Between 10/2013-2/2018, 32 patients (22 BR, 10 LAPC) were treated with this approach. Median age was 70 years. Nine patients were converted to resectability by imaging; six had R0 resections (19%), five (16%) achieved a partial response and 24 (75%) had stable disease. Conclusion: In this small series, the R0 resection rate and response rate were 19% and 16% respectively. These data suggest that neoadjuvant AG may be an alternate option for patients ineligible for FOLFIRINOX.
KW - Gemcitabine
KW - Locally advanced
KW - Nab-paclitaxel
KW - Neoadjuvant
KW - Pancreatic cancer
UR - http://www.scopus.com/inward/record.url?scp=85049792753&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85049792753&partnerID=8YFLogxK
U2 - 10.21873/anticanres.12692
DO - 10.21873/anticanres.12692
M3 - Article
C2 - 29970528
AN - SCOPUS:85049792753
SN - 0250-7005
VL - 38
SP - 4035
EP - 4039
JO - Anticancer Research
JF - Anticancer Research
IS - 7
ER -
